Hui-Min Chang1, Hung-Chin Tsai2, Susan Shin-Jung Lee3, Calvin Kunin4, Pei-Chin Lin1, Shue-Ren Wann3, Yao-Shen Chen3. 1. Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC. 2. Section of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; College of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC; Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC. Electronic address: hctsai1011@yahoo.com.tw. 3. Section of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; College of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. 4. Department of Medicine, Ohio State University, Columbus, OH, USA.
Abstract
BACKGROUND: Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the most effective therapeutic agent for Pneumocystis jirovecii pneumonia (PJP) in patients with AIDS. The major drawback is the frequent occurrence of adverse reactions (ADRs).The current study was designed to determine the frequency and risk factors for TMP/SMX-related ADRs among patients with PJP and AIDS. METHODS: A retrospective study was conducted in adult patients with PJP and AIDS who were admitted to the Veterans General Hospital in, Kaohsiung, Taiwan between January 2006 and December 2011. Charts were reviewed to determine the effect of age, risk behaviors, severity of illness, viral load, CD4 cell counts, use of corticosteroids, and dosage and duration of TMP/SMX on ADRs during hospitalization. Patients who received TMP/SMX for ≤ 5 days or with an incomplete medical record were excluded. Multivariate logistic regression was used to calculate the hazard ratio (HR) for ADRs. RESULTS: Fifty two of 75 patients with PJP and AIDS met the study criteria. Of these patients, 21/52 (40.3%) developed an ADR. Among the 21 patients who suffered an ADR, skin rash was noted in 10 (47.6%), liver function impairment in nine (42.9%), elevated creatinine in eight (38.1%), fever in four (19%), and gastrointestinal symptoms in three (14.3%). Most of the ADRs occurred within the 1(st) 2 weeks of TMP/SMX therapy. Cox proportional hazards analysis revealed that a daily dose of TMP/SMX of ≥ 16 mg/kg (HR, 3.8; 95% confidence interval, 1.40-10.35; p = 0.009) and age 34 years (HR, 4.30; 95% confidence interval, 1.52-12.14; p = 0.006) were independently associated with ADRs. CONCLUSION: We found a high incidence of ADRs among patients with PJP and AIDS treated with TMP/SMX, and most involved the skin and liver. A daily dose of ≥ 16 mg/kg of TMP/SMX and age 34 years were independent risk factors for ADRs.
BACKGROUND:Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the most effective therapeutic agent for Pneumocystis jirovecii pneumonia (PJP) in patients with AIDS. The major drawback is the frequent occurrence of adverse reactions (ADRs).The current study was designed to determine the frequency and risk factors for TMP/SMX-related ADRs among patients with PJP and AIDS. METHODS: A retrospective study was conducted in adult patients with PJP and AIDS who were admitted to the Veterans General Hospital in, Kaohsiung, Taiwan between January 2006 and December 2011. Charts were reviewed to determine the effect of age, risk behaviors, severity of illness, viral load, CD4 cell counts, use of corticosteroids, and dosage and duration of TMP/SMX on ADRs during hospitalization. Patients who received TMP/SMX for ≤ 5 days or with an incomplete medical record were excluded. Multivariate logistic regression was used to calculate the hazard ratio (HR) for ADRs. RESULTS: Fifty two of 75 patients with PJP and AIDS met the study criteria. Of these patients, 21/52 (40.3%) developed an ADR. Among the 21 patients who suffered an ADR, skin rash was noted in 10 (47.6%), liver function impairment in nine (42.9%), elevated creatinine in eight (38.1%), fever in four (19%), and gastrointestinal symptoms in three (14.3%). Most of the ADRs occurred within the 1(st) 2 weeks of TMP/SMX therapy. Cox proportional hazards analysis revealed that a daily dose of TMP/SMX of ≥ 16 mg/kg (HR, 3.8; 95% confidence interval, 1.40-10.35; p = 0.009) and age 34 years (HR, 4.30; 95% confidence interval, 1.52-12.14; p = 0.006) were independently associated with ADRs. CONCLUSION: We found a high incidence of ADRs among patients with PJP and AIDS treated with TMP/SMX, and most involved the skin and liver. A daily dose of ≥ 16 mg/kg of TMP/SMX and age 34 years were independent risk factors for ADRs.
Authors: Todd C Lee; Emily G McDonald; Zahra N Sohani; Guillaume Butler-Laporte; Andrew Aw; Sara Belga; Andrea Benedetti; Alex Carignan; Matthew P Cheng; Bryan Coburn; Cecilia T Costiniuk; Nicole Ezer; Dan Gregson; Andrew Johnson; Kosar Khwaja; Alexander Lawandi; Victor Leung; Sylvain Lother; Derek MacFadden; Michaeline McGuinty; Leighanne Parkes; Salman Qureshi; Valerie Roy; Barret Rush; Ilan Schwartz; Miranda So; Ranjani Somayaji; Darrell Tan; Emilie Trinh Journal: BMJ Open Date: 2022-07-21 Impact factor: 3.006
Authors: Abdul Haseeb; Mohammed A S Abourehab; Wesam Abdulghani Almalki; Abdulrahman Mohammed Almontashri; Sultan Ahmed Bajawi; Anas Mohammed Aljoaid; Bahni Mohammed Alsahabi; Manal Algethamy; Abdullmoin AlQarni; Muhammad Shahid Iqbal; Alaa Mutlaq; Saleh Alghamdi; Mahmoud E Elrggal; Zikria Saleem; Rozan Mohammad Radwan; Ahmad Jamal Mahrous; Hani Saleh Faidah Journal: Int J Environ Res Public Health Date: 2022-02-28 Impact factor: 3.390